Latest Breaking News On - Jianmin fang - Page 4 : comparemela.com

RemeGen s Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment

YANTAI, China, Dec. 28, 2023 /PRNewswire/ RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company,

United statesJianmin fangEuropean unionDrug administrationRemegen coInvestigational new drugPlatinum resistant recurrent ovarian cancer

RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients

RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesDisitamab vedotinJianmin fangPrnewswire remegen coChina national healthcare security administrationRemegen coSeagen incNational medical products administrationChina national medical products administrationChina national reimbursement drug listRemegen co ltdNational reimbursement drug listGen announces continued inclusionEnsuring continuous accessibilityInnovative drugsInvestigational new drug

RemeGen Announces Publication of Results from Two Phase II Studies for Disitamab Vedotin in Latest Issue of Journal of Clinical Oncology (JCO)

/PRNewswire/ RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced its two Phase.

United statesGuo junJianmin fangDisitamab vedotinSeagen incNational medical products administrationRemegen co ltdRemegen coPrnewswire remegen coClinical oncologyInvestigational new drugLooking statementsRemegen co

Remegen s Innovative New Drug Telitacicept(RC18) Obtains Positive Phase III Results, Submitted for Second Indication for Treatment of Rheumatoid Arthritis

/PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, recently.

United statesJianmin fangPrnewswire remegen co ltdChina national medical products administrationRemegen coNational medical products administrationRemegen co ltdChief scientific officerSullivan reportBrand nameRemegen co

RemeGen s Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren s Syndrome: Findings Published in Prestigious Rheumatology Journal

/PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, has.

United kingdomUnited statesZeng xiaofengJianmin fangUnion medical college hospitalDepartment of rheumatologyOxford universityRemegen coBritish society for rheumatologyOxford university pressPrnewswire remegen co ltdBritish societyProfessor zeng xiaofengPeking union medical college hospitalChief scientific officerRemegen co